Recent developments in our understanding of how platelet-derived growth factor (PDGF) and its receptors contribute to proliferative vitreoretinopathy

Experimental Eye Research

Volumn 90, Issue 3, 2010, Pages 376-381

  Lei, Hetian ^a   Rheaume, Marc Andre ^a   Kazlauskas, Andrius ^a  

^a SCHEPENS EYE RESEARCH INSTITUTE   (United States)

Author keywords

Growth factors; Platelet derived growth factor; Platelet derived growth factor receptor; Proliferative vitreoretinopathy; Signal transduction

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; CYTOKINE; DAUNORUBICIN; FLUOROURACIL; GROWTH FACTOR; LOW MOLECULAR WEIGHT HEPARIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PLASMIN; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR C; PLATELET DERIVED GROWTH FACTOR RECEPTOR; REACTIVE OXYGEN METABOLITE; SCLEROPROTEIN;

CLINICAL STUDY; DISEASE COURSE; DRUG TOLERABILITY; ENZYME ACTIVATION; ENZYME ACTIVITY; EPIRETINAL MEMBRANE; EXPERIMENTAL STUDY; HUMAN; NONHUMAN; PATHOGENESIS; PHOSPHORYLATION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RABBIT; RECURRENT DISEASE; RETINA DETACHMENT; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; TREATMENT FAILURE; VISUAL ACUITY; VITREORETINOPATHY; VITREOUS BODY;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; PLATELET-DERIVED GROWTH FACTOR; RABBITS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RETINAL DETACHMENT; SIGNAL TRANSDUCTION; VITREORETINOPATHY, PROLIFERATIVE;

EID: 77649186388     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exer.2009.11.003     Document Type: Review

References (69)

1. Agrawal R.N., He S., Spee C., Cui J.Z., Ryan S.J., Hinton D.R. In vivo models of proliferative vitreoretinopathy. Nat. Protoc. 2007, 2:67-77.
2. Akiyama H., Kachi S., Silva R.L., Umeda N., Hackett S.F., McCauley D., McCauley T., Zoltoski A., Epstein D.M., Campochiaro P.A. Intraocular injection of an aptamer that binds PDGF-B: a potential treatment for proliferative retinopathies. J. Cell Physiol. 2006, 207:407-412.
3. Andrews A., Balciunaite E., Leong F.L., Tallquist M., Soriano P., Refojo M., Kazlauskas A. Platelet-derived growth factor plays a key role in proliferative vitreoretinopathy. Invest. Ophthalmol. Vis. Sci. 1999, 40:2683-2689.
4. Asaria R.H., Kon C.H., Bunce C., Charteris D.G., Wong D., Khaw P.T., Aylward G.W. Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: results from a randomized, double-blind, controlled clinical trial. Ophthalmol. 2001, 108:1179-1183.
5. Asaria R.H., Kon C.H., Bunce C., Sethi C.S., Limb G.A., Khaw P.T., Aylward G.W., Charteris D.G. Silicone oil concentrates fibrogenic growth factors in the retro-oil fluid. Br. J. Ophthalmol. 2004, 88:1439-1442.
6. Banerjee S., Savant V., Scott R.A., Curnow S.J., Wallace G.R., Murray P.I. Multiplex bead analysis of vitreous humor of patients with vitreoretinal disorders. Invest. Ophthalmol. Vis. Sci. 2007, 48:2203-2207.
7. Baudouin C., Fredj-Reygrobellet D., Brignole F., Negre F., Lapalus P., Gastaud P. Growth factors in vitreous and subretinal fluid cells from patients with proliferative vitreoretinopathy. Ophthal. Res. 1993, 25:52-59.
8. Byer N.E. The natural history of senile retinoschisis. Trans. Sect. Ophthalmol. Am. Acad. Ophthalmol. Otolaryngol. 1976, 81:458-471.
9. Campochiaro P. The Pathogenesis Of Proliferative Vitreoretinopathy 2006, Elsevier Mosby, Philadelphia.
10. Campochiaro P.A., Hackett S.F., Vinores S.A. Growth Factors in the Retina and Retinal Pigmented Epithelium. Progress in Retinal and Eye Research 1996, Elsevier Science Ltd., pp. 547-567.
11. Charteris D.G. Growth factors in proliferative vitreoretinopathy. Br. J. Ophthalmol. 1998, 82:106.
12. Choudhury P., Chen W., Hunt R.C. Production of platelet-derived growth factor by interleukin-1β and transforming growth factor-β-stimulated retinal pigment epithelial cells leads to contraction of collagen gels. Invest. Ophthalmol. Vis. Sci. 1997, 38:824-833.
13. Cowley M., Conway B.P., Campochiaro P.A., Kaiser D., Gaskin H. Clinical risk factors for proliferative vitreoretinopathy. Arch. Ophthalmol. 1989, 107:1147-1151.
14. Cox M.S., Schepens C.L., Freeman H.M. Retinal detachment due to ocular contusion. Arch. Ophthalmol. 1966, 76:678-685.
15. Cui J.Z., Chiu A., Maberley D., Ma P., Samad A., Matsubara J.A. Stage specificity of novel growth factor expression during development of proliferative vitreoretinopathy. Eye 2007, 21:200-208.
16. Cui J., Lei H., Samad A., Basavanthappa S., Maberley D., Matsubara J., Kazlauskas A. PDGF receptors are activated in human epiretinal membranes. Exp. Eye Res. 2009, 88:438-444.
17. Dieudonne S.C., La Heij E.C., Diederen R., Kessels A.G., Liem A.T., Kijlstra A., Hendrikse F. High TGF-beta2 levels during primary retinal detachment may protect against proliferative vitreoretinopathy. Invest. Ophthalmol. Vis. Sci. 2004, 45:4113-4118.
18. Duquesne N., Bonnet M., Adeleine P. Preoperative vitreous hemorrhage associated with rhegmatogenous retinal detachment: a risk factor for postoperative proliferative vitreoretinopathy?. Graefes Arch. Clin. Exp. Ophthalmol. 1996, 234:677-682.
19. El-Ghrably I.A., Dua H.S., Orr G.M., Fischer D., Tighe P.J. Intravitreal invading cells contribute to vitreal cytokine milieu in proliferative vitreoretinopathy. Br. J. Ophthalmol. 2001, 85:461-470.
20. Elner S.G., Elner V.M., Jaffe G.J., Stuart A., Kunkel S.L., Strieter R.M. Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Curr. Eye Res. 1995, 14:1045-1053.
21. Fredriksson L., Li H., Eriksson U. The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev. 2004, 15:197-204.
22. Fredriksson L., Li H., Fieber C., Li X., Eriksson U. Tissue plasminogen activator is a potent activator of PDGF-CC. Embo J. 2004, 23:3793-3802.
23. Gilbertson D.G., Duff M.E., West J.W., Kelly J.D., Sheppard P.O., Hofstrand P.D., Gao Z., Shoemaker K., Bukowski T.R., Moore M., Feldhaus A.L., Humes J.M., Palmer T.E., Hart C.E. Platelet-derived growth factor C (PDGF-C), a novel growth factor that binds to PDGF alpha and beta receptor. J. Biol. Chem. 2001, 276:27406-27414.
24. Girard P., Mimoun G., Karpouzas I., Montefiore G. Clinical risk factors for proliferative vitreoretinopathy after retinal detachment surgery. Retina 1994, 14:417-424.
25. Han D. Proliferative Vitreoretinopathy 2008, Elsevier Saunders, Philadelphia.
26. Harada C., Mitamura Y., Harada T. The role of cytokines and trophic factors in epiretinal membranes: involvement of signal transduction in glial cells. Prog. Retin. Eye Res. 2006, 25:149-164.
27. Heeneman S., Haendeler J., Saito Y., Ishida M., Berk B.C. Angiotensin II induces transactivation of two different populations of the platelet-derived growth factor beta receptor. Key role for the p66 adaptor protein Shc. J. Biol. Chem. 2000, 275:15926-15932.
28. Heldin C.-H., Westermark B. Platelet-derived growth factor: mechanism of action and possible in vivo function. Cell Regul. 1990, 1:555-566.
29. Herrlich A., Daub H., Knebel A., Herrlich P., Ullrich A., Schultz G., Gudermann T. Ligand-independent activation of platelet-derived growth factor receptor is a necessary intermediate in lysophosphatidic, acid-stimulated mitogenic activity in L cells. Proc. Natl. Acad. Sci. 1998, 95:8985-8990.
30. Hinton D.R., He S., Jin M.L., Barron E., Ryan S.J. Novel growth factors involved in the pathogenesis of proliferative vitreoretinopathy. Eye 2002, 16:422-428.
31. Ikuno Y., Leong F.L., Kazlauskas A. Attenuation of experimental proliferative vitreoretinopathy by inhibiting the platelet-derived growth factor receptor. Invest. Ophthalmol. Vis. Sci. 2000, 41:3107-3116.
32. Ikuno Y., Leong F.L., Kazlauskas A. PI3K and PLCgamma play a central role in experimental PVR. Invest. Ophthalmol. Vis. Sci. 2002, 43:483-489.
33. Ikuno Y., Kazlauskas A. An in vivo gene therapy approach for experimental proliferative vitreoretinopathy using the truncated platelet-derived growth factor alpha receptor. Invest. Ophthalmol. Vis. Sci. 2002, 43:2406-2411.
34. Kerkhoff F.T., Lamberts Q.J., van den Biesen P.R., Rothova A. Rhegmatogenous retinal detachment and uveitis. Ophthalmology 2003, 110:427-431.
35. Kita T., Hata Y., Miura M., Kawahara S., Nakao S., Ishibashi T. Functional characteristics of connective tissue growth factor on vitreoretinal cells. Diabetes 2007, 56:1421-1428.
36. Klinghoffer R.A., Sachsenmaier C., Cooper J.A., Soriano P. Src family kinases are required for integrin but not PDGFR signal transduction. Embo J. 1999, 18:2459-2471.
37. Kon C.H., Occleston N.L., Aylward G.W., Khaw P.T. Expression of vitreous cytokines in proliferative vitreoretinopathy: a prospective study. Invest. Ophthalmol. Vis. Sci. 1999, 40:705-712.
38. La Heij E.C., van de Waarenburg M.P., Blaauwgeers H.G., Kessels A.G., Liem A.T., Theunissen C., Steinbusch H., Hendrikse F. Basic fibroblast growth factor, glutamine synthetase, and interleukin-6 in vitreous fluid from eyes with retinal detachment complicated by proliferative vitreoretinopathy. Am. J. Ophthalmol. 2002, 134:367-375.
39. Lashkari K., Rahimi N., Kazlauskas A. Hepatocyte growth factor receptor in human RPE cells: implications in proliferative vitreoretinopathy. Invest. Ophthalmol. Vis. Sci. 1999, 40:149-156.
40. Lei H., Hovland P., Velez G., Haran A., Gilbertson D., Hirose T., Kazlauskas A. A potential role for PDGF-C in experimental and clinical proliferative vitreoretinopathy. Invest. Ophthalmol. Vis. Sci. 2007, 48:2335-2342.
41. Lei H., Velez G., Hovland P., Hirose T., Kazlauskas A. Plasmin is the major protease responsible for processing PDGF-C in the vitreous of patients with proliferative vitreoretinopathy. Invest. Ophthalmol. Vis. Sci. 2008, 49:42-48.
42. Lei, H., Velez, G., Cui, J., Samad, A., Maberley, D., Matsubara, J., Kazlauskas, A., N-acetylcysteine suppresses retinal contraction in an experimental model of proliferative vitreoretinopathy, submitted for publication.
43. Lei H., Velez G., Hovland P., Hirose T., Gilbertson D., Kazlauskas A. Growth factors outside the PDGF family drive experimental PVR. Invest. Ophthalmol. Vis. Sci. 2009, 50:3394-3403.
44. Lei H., Kazlauskas A. Growth factors outside of the platelet-derived growth factor (PDGF) family employ reactive oxygen species/Src family kinases to activate PDGF receptor alpha and thereby promote proliferation and survival of cells. J. Biol. Chem. 2009, 284:6329-6336.
45. Linseman D.A., Benjamin C.W., Jones D.A. Convergence of angiotensin II and platelet-derived growth factor receptor signaling cascades in vascular smooth muscle cells. J. Biol. Chem. 1995, 270:12563-12568.
46. Liou G.I., Pakalnis V.A., Matragoon S., Samuel S., Behzadian M.A., Baker J., Khalil I.E., Roon P., Caldwell R.B., Hunt R.C., Marcus D.M. HGF regulation of RPE proliferation in an IL-1beta/retinal hole-induced rabbit model of PVR. Mol. Vis. 2002, 8:494-501.
47. Liu Y., Li M., Warburton R.R., Hill N.S., Fanburg B.L. The 5-HT transporter transactivates the PDGFbeta receptor in pulmonary artery smooth muscle cells. Faseb J. 2007, 21:2725-2734.
48. Matsui T., Heidaran M., Miki T., Popescu N., LaRochelle W., Kraus M., Pierce J., Aaronson S. Isolation of a novel receptor cDNA establishes the existence of two PDGF receptor genes. Science 1989, 243:800-804.
49. Mukherjee S., Guidry C. The insulin-like growth factor system modulates retinal pigment epithelial cell tractional force generation. Invest. Ophthalmol. Vis. Sci. 2007, 48:1892-1899.
50. Oh K., Hartnett M., Landers M.B. Pathogenic Mechanisms of Retinal Detachment 2006, Elsevier Mosby, Philadelphia.
51. Oshima Y., Sakamoto T., Hisatomi T., Tsutsumi C., Ueno H., Ishibashi T. Gene transfer of soluble TGF-beta type II receptor inhibits experimental proliferative vitreoretinopathy. Gene Ther. 2002, 9:1214-1220.
52. Raines, E.W., Bowen-Pope, D.F., Ross, R., 1990. Peptide growth factors and their receptors.
53. Reigstad L.J., Varhaug J.E., Lillehaug J.R. Structural and functional specificities of PDGF-C and PDGF-D, the novel members of the platelet-derived growth factors family. Febs J. 2005, 272:5723-5741.
54. Robbins S.G., Mixon R.N., Wilson D.J., Hart C.E., Robertson J.E., Westra I., Planck S.R., Rosenbaum J.T. Platelet-derived growth factor ligands and receptors immunolocalized in proliferative retinal diseases. Invest. Ophthalmol. Vis. Sci. 1994, 35(No 10):3649-3663.
55. Rodriguez-Viciana P., Warne P.H., Dhand R., Vanhaesebroeck B., Gout I., Fry M.J., Waterfield M.D., Downward J. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 1994, 370:527-532. [see comments].
56. Rodriguez-Viciana P., Warne P.H., Vanhaesebroeck B., Waterfield M.D., Downward J. Activation of phosphoinositide 3-kinase by interaction with Ras and by point mutation. Embo J. 1996, 15:2442-2451.
57. Rosenkranz S., Kazlauskas A. Evidence for distinct signaling properties and biological responses induced by the PDGF receptor alpha and beta subtypes. Growth Factors 1999, 16:201-216.
58. Schiff W.M., Hwang J.C., Ober M.D., Olson J.L., Dhrami-Gavazi E., Barile G.R., Chang S., Mandava N. Safety and efficacy assessment of chimeric ribozyme to proliferating cell nuclear antigen to prevent recurrence of proliferative vitreoretinopathy. Arch. Ophthalmol. 2007, 125:1161-1167.
59. Siegbahn A., Johnell M., Nordin A., Aberg M., Velling T. TF/FVIIa transactivate PDGFRbeta to regulate PDGF-BB-induced chemotaxis in different cell types: involvement of Src and PLC. Arterioscler Thromb. Vasc. Biol. 2008, 28:135-141.
60. Stickler G.B., Hughes W., Houchin P. Clinical features of hereditary progressive arthro-ophthalmopathy (Stickler syndrome): a survey. Genet. Med. 2001, 3:192-196.
61. Sundaresan M., Yu Z.X., Ferrans V.J., Irani K., Finkel T. Requirement for generation of H2O2 for platelet-derived growth factor signal transduction. Science 1995, 270:296-299.
62. Tallquist M., Kazlauskas A. PDGF signaling in cells and mice. Cytokine Growth Factor Rev. 2004, 15:205-213.
63. Tanimoto T., Lungu A.O., Berk B.C. Sphingosine 1-phosphate transactivates the platelet-derived growth factor beta receptor and epidermal growth factor receptor in vascular smooth muscle cells. Circ. Res. 2004, 94:1050-1058.
64. Thompson J. Proliferative Vitreoretinopathy 2006, Elsevier Mosby, Philadelphia.
65. Wiedemann P., Hilgers R.D., Bauer P., Heimann K. Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial. Daunomycin Study Group. Am. J. Ophthalmol. 1998, 126:550-559.
66. Wolfensberger T.J., Gonvers M. Surgical treatment of retinal detachment owing to macular hole. Semin. Ophthalmol. 2000, 15:122-127.
67. Yanyali A., Bonnet M. Risk factors of postoperative proliferative vitreoretinopathy in giant tears. J. Fr. Ophtalmol. 1996, 19:175-180.
68. Zhang H., Bajraszewski N., Wu E., Wang H., Moseman A.P., Dabora S.L., Griffin J.D., Kwiatkowski D.J. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J. Clin. Invest. 2007, 117:730-738.
69. Zheng Y., Ikuno Y., Ohj M., Kusaka S., Jiang R., Cekic O., Sawa M., Tano Y. Platelet-derived growth factor receptor kinase inhibitor AG1295 and inhibition of experimental proliferative vitreoretinopathy. Jpn. J. Ophthalmol. 2003, 47:158-165.